TEMECULA, CA--(Marketwire - Jul 25, 2012) - FFF Enterprises, Inc., the nation's largest and most trusted distributor of plasma products, vaccines and critical-care biopharmaceuticals, announced today the appointment of John H. McAlpine to the position of Chief Financial Officer. John replaces Earl Culver who recently retired after over a decade of valued service with FFF.
McAlpine comes to FFF with a wealth of financial management expertise. With more than 25 years of experience encompassing treasury, tax, financial analysis, and risk management, McAlpine has already made significant contributions in both international and domestic companies and the private middle market sector.
"What is intriguing about FFF's business model -- and what attracted me to the company -- is its unique ability to allow every team member the opportunity to positively affect the lives of patients who depend on the products it distributes," says McAlpine. "I am excited to become a part of the FFF leadership team."
Prior to joining FFF, John's experience includes three years as Vice President and Chief Financial Officer at AmerisourceBergen Drug Company, a pharmaceutical distribution company with approximately $40 billion in operating revenue. Other career highlights include serving most recently as Executive Vice President and Chief Financial Officer at Telmar Network Technology, Inc., a $150 million global telecommunications company, and Executive Vice President, Chief Financial Officer and Director at Targus Group International, Inc., a $500 million worldwide market leader of notebook carrying cases and computer accessories.
"John's addition to FFF comes at a great time to not only replace the retiring Earl Culver but to assist in managing the growth phase we are experiencing," says Patrick M. Schmidt, president and chief executive officer, FFF Enterprises, Inc. "His character, energy and related experience make him a great fit for us."
About FFF Enterprises, Inc.
Temecula-based FFF Enterprises is the largest and most trusted distributor of plasma products, vaccines and other biopharmaceuticals in the U.S. Founded in 1988, FFF is now in its 25th year with more than a billion dollars in annual sales and a flawless safety track record. FFF has taken a leadership position in regards to supply chain safety and innovation, setting new standards and pioneering industry firsts. FFF's commitment to Guaranteed Channel Integrity™ ensures that products are purchased only from the manufacturer and shipped only to healthcare providers, with additional steps taken to safely store, handle and ship products to ensure patient safety is never compromised. FFF's proprietary systems, Verified Electronic Pedigree™ and Lot-Track™, provide verification of this secure channel, and FFF's MyFluVaccine (www.MyFluVaccine.com) and VaxAmerica (www.VaxAmerica.com) are revolutionary vaccination programs that have added a new level of safety, convenience and reliability to both healthcare providers and consumers.